Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity (WoO) study
Oncopeptides AB (publ), a biotech company specializing in difficult-to-treat cancers, today announces data from the first patients in its ongoing clinical Window-of-Opportunity (WoO) study, OP-701 (INSULA), evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma.
Read original article on The Medical News →Related news
-
T-cell research reveals paths to better vaccines for COVID-19 and beyond
-
New signaling pathway enhances blood stem cell transplantation outcomes
-
Insuficiência cardíaca: do diagnóstico ao tratamento | VEJA e Cuide-se
-
Cutting sugary drinks helps reduce childhood obesity, study finds
-
The 9 Best Amazon Bedsheets for a Luxurious Night’s Sleep
-
Despite the controversy, data centers could be attractive to struggling rural towns
-
Cyberbullying acts as an extension of in-person school violence
-
Masked high blood pressure linked to higher risk of falls in older adults